New trial data adds support for Entereg
Shares of Exton, PA-based Adolor soared on positive data from a pivotal trial for Entereg, a drug in development with GlaxoSmithKline to speed gastrointestinal recovery following surgery. Entereg had been the subject of an FDA "approvable" letter last July, though the agency had requested more data on the drug before it could be approved. The new data on a trial involving 654 patients showed that patients taking Entereg demonstrated a statistically significant improved response compared to patients receiving a placebo. Researchers say they will file a full response to the FDA by June.
- read this article from the Philadelphia Inquirer for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
